2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On June 5, 2017, KEI provided comments to the NIH/NCI, on a prospective grant of an exclusive license to PathoVax, relating to HPV vaccines. On July 10,… Continue Reading